Xbrane Biopharma AB

Equities

XBRANE

SE0007789409

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:59:52 2024-03-28 am EDT 5-day change 1st Jan Change
0.3015 SEK +3.97% Intraday chart for Xbrane Biopharma AB -52.22% -96.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index CI
Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024
Xbrane Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Xbrane Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xbrane Biopharma AB(OM:XBRANE) added to OMX Nordic Small Cap Index CI
Xbrane Biopharma AB Announces Appointment of Nomination Committee CI
Transcript : Xbrane Biopharma AB, Nine Months 2023 Earnings Call, Nov 30, 2023
Xbrane Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Xbrane Biopharma AB Focuses on Development Portfolio and Introduces A Cost-Savings Scheme CI
Xbrane Biopharma AB Presents Nomination Committee CI
Transcript : Xbrane Biopharma AB, H1 2023 Earnings Call, Aug 29, 2023
Xbrane Biopharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Certain Shares of Xbrane Biopharma AB are subject to a Lock-Up Agreement Ending on 21-AUG-2023. CI
Certain Shares of Xbrane Biopharma AB are subject to a Lock-Up Agreement Ending on 21-AUG-2023. CI
Transcript : Xbrane Biopharma AB - Shareholder/Analyst Call
US FDA Accepts Xbrane Biopharma’s Filing for Eye Disease Inhibitor MT
Xbrane Biopharma AB Announces U.S. FDA Filing Acceptance for A Lucentis®? (Rranibizumab) Biosimilar Candidate CI
Transcript : Xbrane Biopharma AB, Q1 2023 Earnings Call, May 31, 2023
Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Xbrane Biopharma, Stada Jointly Launch Lucentis Biosimilar in Germany MT
STADA Arzneimittel Aktiengesellschaft and Xbrane Biopharma AB Launch Ximluci® as Ranibizumab Biosimilar in Germany CI
Xbrane Biopharma Files Biologics License Application With US FDA for Biosimilar Candidate Lucentis MT
Xbrane Biopharma AB Submits BLA for Runibizumab Biosimilar Candidate to FDA CI
STADA Arzneimittel Aktiengesellschafta and Xbrane Biopharma AB Launch Ranibizumab to Support Patient Access in Europe CI
Xbrane Biopharma AB Auditor Raises 'Going Concern' Doubt CI
Chart Xbrane Biopharma AB
More charts
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3015 SEK
Average target price
0.75 SEK
Spread / Average Target
+148.76%
Consensus
  1. Stock
  2. Equities
  3. Stock Xbrane Biopharma AB - Nasdaq Stockholm
  4. News Xbrane Biopharma AB
  5. EU Clears Xbrane-STADA's Biosimilar of Novartis' Eye Drug Lucentis